semaglutide vision Last month, the European Medicines Agency recommended that product information for #semaglutide medicines— the active ingredient in #Ozempic, #Rybelsus, and #Wegovy — be updated to include non-arteritic anterior ischemic optic neuropathy or # Swiss study adds to concern

Healthcare providers may consider: Bacterial culture if infection is suspected Temporary discontinuation of semaglutide to assess symptom resolution Referral to allergy/immunology for suspected hypersensitivity reactions For type 2 diabetes patients only, alternative GLP-1 receptor agonist formulations (such as oral semaglutide/Rybelsus) if injection site reactions are recurrent and problematic Patients with confirmed hypersensitivity to semaglutide should not continue the medication

2): In rodents, there are sufficient GLP-1 receptors on thyroid C cells to increase cAMP production upon exposure to GLP-1 or other GLP-1 receptor agonists

Le GLP-1 est une hormone intestinale de la famille des incrtines, principalement connue pour stimuler la scrtion d'insuline en fonction du glucose prsent dans le sang

Endocrinol Diabetes Metab Case Rep

Untested federations (NPC/IFBB) don't screen for GLP-1 medications